Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin

Cerebral Cortex

Volumn 24, Issue 12, 2014, Pages 3221-3231

  Bernasconi, Fosco ^a   Schmidt, André ^a   Pokorny, Thomas ^a   Kometer, Michael ^a   Seifritz, Erich ^a   Vollenweider, Franz X ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

5 HT1A 2A receptors; EEG; Emotional face processing; Psilocybin; Source estimation

Indexed keywords

PLACEBO; PSILOCYBINE; SEROTONIN AGONIST;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ELECTRIC FIELD; ELECTROENCEPHALOGRAPHY; EMOTION; EMOTIONAL FACE PROCESSING; EVOKED VISUAL RESPONSE; FACIAL EXPRESSION; FEAR; FEMALE; HAPPINESS; HUMAN; HUMAN EXPERIMENT; LIMBIC CORTEX; MALE; NEUROIMAGING; NEUROMODULATION; NORMAL HUMAN; PARAHIPPOCAMPAL GYRUS; POSTERIOR CINGULATE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; RECOGNITION; SEROTONINERGIC SYSTEM; TEMPORAL CORTEX; VISUAL STIMULATION; ANALYSIS OF VARIANCE; BRAIN MAPPING; DRUG EFFECTS; FACE; PATTERN RECOGNITION; QUESTIONNAIRE; TEMPORAL LOBE; YOUNG ADULT;

ADULT; ANALYSIS OF VARIANCE; BRAIN MAPPING; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EMOTIONS; EVOKED POTENTIALS, VISUAL; FACE; FEMALE; HUMANS; MALE; PATTERN RECOGNITION, VISUAL; PSILOCYBINE; PSYCHOMETRICS; QUESTIONNAIRES; SEROTONIN RECEPTOR AGONISTS; TEMPORAL LOBE; YOUNG ADULT;

EID: 84920774898     PISSN: 10473211     EISSN: 14602199     Source Type: Journal    
DOI: 10.1093/cercor/bht178     Document Type: Article

References (84)

1. Adolphs R. 2002. Recognizing emotion from facial expressions: psychological and neurological mechanisms. Behav Cogn Neurosci Rev. 1:21-62.
2. Anderson IM, Del-Ben CM, McKie S, Richardson P, Williams SR, Elliott R, Deakin JF. 2007. Citalopram modulation of neuronal responses to aversive face emotions: a functional MRI study. Neuroreport. 18:1351-1355.
3. Arce E, Simmons AN, Lovero KL, Stein MB, Paulus MP. 2008. Escitalopram effects on insula and amygdala BOLD activation during emotional processing. Psychopharmacology (Berl). 196:661-672.
4. Ary JP, Klein SA, Fender DH. 1981. Location of sources of evoked scalp potentials: corrections for skull and scalp thicknesses. IEEE Trans Biomed Eng. 28:447-452.
5. Batty M, Taylor MJ. 2003. Early processing of the six basic facial emotional expressions. Brain Res Cogn Brain Res. 17:613-620.
6. Bayle DJ, Taylor MJ. 2010. Attention inhibition of early cortical activation to fearful faces. Brain Res. 1313:113-123.
7. Bernasconi F, De LM, Tzovara A, Manuel AL, Murray MM, Spierer L. 2011. Noise in brain activity engenders perception and influences discrimination sensitivity. J Neurosci. 31:17971-17981.
8. Bishop SJ. 2008. Neural mechanisms underlying selective attention to threat. Ann N Y Acad Sci. 1129:141-152.
9. Bressler SL, Tang W, Sylvester CM, Shulman GL, Corbetta M. 2008. Top-down control of human visual cortex by frontal and parietal cortex in anticipatory visual spatial attention. J Neurosci. 28:10056-10061.
10. Browning M, Reid C, Cowen PJ, Goodwin GM, Harmer CJ. 2007. A single dose of citalopram increases fear recognition in healthy subjects. J Psychopharmacol. 21:684-690.
11. Bruhl AB, Kaffenberger T, Herwig U. 2010. Serotonergic and noradrenergic modulation of emotion processing by single dose antidepressants. Neuropsychopharmacology. 35:521-533.
12. Brunet D, Murray MM, Michel CM. 2011. Spatiotemporal analysis of multichannel EEG: CARTOOL. Comput Intell Neurosci. 2011:813870.
13. Cappe C, Thelen A, Romei V, Thut G, Murray MM. 2012. Looming signals reveal synergistic principles of multisensory integration. J Neurosci. 32:1171-1182.
14. Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, Tyacke RJ, Leech R, Malizia AL, Murphy K et al. 2012. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci USA. 109:2138-2143.
15. Carhart-Harris RL, Leech R, Williams TM, Erritzoe D, Abbasi N, Bargiotas T, Hobden P, Sharp DJ, Evans J, Feilding A et al. 2012. Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. Br J Psychiatry. 200:238-244.
16. Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX. 2005. Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci. 17:1497-1508.
17. Day-Brown JD, Wei H, Chomsung RD, Petry HM, Bickford ME. 2010. Pulvinar projections to the striatum and amygdala in the tree shrew. Front Neuroanat. 4:143.
18. Del-Ben CM, Deakin JF, McKie S, Delvai NA, Williams SR, Elliott R, Dolan M, Anderson IM. 2005. The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study. Neuropsychopharmacology. 30:1724-1734.
19. De Lucia M, Clarke S, Murray MM. 2010. A temporal hierarchy for conspecific vocalization discrimination in humans. J Neurosci. 30(33):11210-11221.
20. Derogatis L. 1994. SCL-90-R: Symptom Checklist-90-R. Administration, scoring and procedures manual. Minneapolis: National Computer Systems.
21. Dima D, Stephan KE, Roiser JP, Friston KJ, Frangou S. 2011. Effective connectivity during processing of facial affect: evidence for multiple parallel pathways. J Neurosci. 31:14378-14385.
22. Disner SG, Beevers CG, Haigh EA, Beck AT. 2011. Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci. 12:467-477.
23. Dittrich A. 1998. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry. 31(Suppl 2):80-84.
24. Ekman P, Friesen W. 1976. Pictures of facial affect. Palo Alto: Consulting Psychologists.
25. Ekman P, Friesen WV, O'Sullivan M, Chan A, Diacoyanni-Tarlatzis I, Heider K, Krause R, Le Compte WA, Pitcairn T et al. 1987. Universals and cultural differences in the judgments of facial expressions of emotion. J Pers Soc Psychol. 53:712-717.
26. Elliott R, Zahn R, Deakin JF, Anderson IM. 2011. Affective cognition and its disruption in mood disorders. Neuropsychopharmacology. 36:153-182.
27. Fusar-Poli P, Placentino A, Carletti F, Landi P, Allen P, Surguladze S, Benedetti F, Abbamonte M, Gasparotti R, Barale F et al. 2009. Functional atlas of emotional faces processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging studies. J Psychiatry Neurosci. 34:418-432.
28. Gouzoulis-Mayfrank E, Thelen B, Maier S, Heekeren K, Kovar KA, Sass H, Spitzer M. 2002. Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans. Neuropsychobiology. 45:205-212.
29. Grave de Peralta MR, Gonzalez AS, Lantz G, Michel CM, Landis T. 2001. Noninvasive localization of electromagnetic epileptic activity. I. Method descriptions and simulations. Brain Topogr. 14:131-137.
30. Grave de Peralta MR, Murray MM, Michel CM, Martuzzi R, Gonzalez Andino SL. 2004. Electrical neuroimaging based on biophysical constraints. Neuroimage. 21:527-539.
31. Guthrie D, Buchwald JS. 1991. Significance testing of difference potentials. Psychophysiology. 28:240-244.
32. Harmer CJ, Bhagwagar Z, Cowen PJ, Goodwin GM. 2002. Acute administration of citalopram facilitates memory consolidation in healthy volunteers. Psychopharmacology (Berl). 163:106-110.
33. Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM. 2006. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry. 59:816-820.
34. Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM. 2004. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry. 161:1256-1263.
35. Harmer CJ. 2008. Serotonin and emotional processing: does it help explain antidepressant drug action? Neuropharmacology. 55:1023-1028.
36. Haxby JV, Hoffman EA, Gobbini MI. 2000. The distributed human neural system for face perception. Trends Cogn Sci. 4:223-233.
37. Hillyard SA, nllo-Vento L. 1998. Event-related brain potentials in the study of visual selective attention. Proc Natl Acad Sci USA. 95:781-787.
38. Jaworska N, Thompson A, Shah D, Fisher D, Ilivitsky V, Knott V. 2010. Electrocortical effects of acute tryptophan depletion on emotive facial processing in depression-prone individuals. Eur Neuropsychopharmacol. 20:473-486.
39. Johnstone T, van Reekum CM, Urry HL, Kalin NH, Davidson RJ. 2007. Failure to regulate: counterproductive recruitment of top-down prefrontal-subcortical circuitry in major depression. J Neurosci. 27:8877-8884.
40. Kerestes R, Labuschagne I, Croft RJ, O'Neill BV, Bhagwagar Z, Phan KL, Nathan PJ. 2009. Evidence for modulation of facial emotional processing bias during emotional expression decoding by serotonergic and noradrenergic antidepressants: an event-related potential (ERP) study. Psychopharmacology (Berl). 202:621-634.
41. Knebel JF, Javitt DC, Murray MM. 2011. Impaired early visual response modulations to spatial information in chronic schizophrenia. Psychiatry Res. 193:168-176.
42. Koenig T, Kottlow M, Stein M, Melie-Garcia L. 2011. Ragu: a free tool for the analysis of EEG and MEG event-related scalp field data using global randomization statistics. Comput Intell Neurosci. 2011:938925.
43. Koenig T, Melie-Garcia L. 2010. A method to determine the presence of averaged event-related fields using randomization tests. Brain Topogr. 23:233-242.
44. Kometer M, Cahn BR, Andel D, Carter OL, Vollenweider FX. 2011. The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Biol Psychiatry. 69(5):399-406.
45. Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX. 2012. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry. 72:898-906.
46. Labuschagne I, Croft RJ, Phan KL, Nathan PJ. 2010. Augmenting serotonin neurotransmission with citalopram modulates emotional expression decoding but not structural encoding of moderate intensity sad facial emotional stimuli: an event-related potential (ERP) investigation. J Psychopharmacol. 24:1153-1164.
47. Lehmann D. 1987. Handbook of electroencephalography and clinical neurophysiology. In: Gevins AS, Remond A, editors. Methods of analysis of brain electrical magnetic signals, Principles of spatial analysis. Vol. 1. Amsterdam: Elsevier. p 309-354.
48. Lehmann D, Skrandies W. 1980. Reference-free identification of components of checkerboard-evoked multichannel potential fields. Electroencephalogr Clin Neurophysiol. 48:609-621.
49. Luck SJ, Woodman GF, Vogel EK. 2000. Event-related potential studies of attention. Trends Cogn Sci. 4:432-440.
50. Michel CM, Koenig T, Brandeis D, Gianotti R R L, Wackermann. 2009. Electrical Neuroimaging. Cambridge: Cambridge University Press.
51. Michel CM, Murray MM, Lantz G, Gonzalez S, Spinelli L, Grave de PR. 2004. EEG source imaging. Clin Neurophysiol. 115:2195-2222.
52. Millan MJ. 2006. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther. 110:135-370.
53. Murphy SE, Norbury R, O'Sullivan U, Cowen PJ, Harmer CJ. 2009. Effect of a single dose of citalopram on amygdala response to emotional faces. Br J Psychiatry. 194:535-540.
54. Murray MM, Brunet D, Michel CM. 2008. Topographic ERP analyses: a step-by-step tutorial review. Brain Topogr. 20:249-264.
55. Nichols DE. 2004. Hallucinogens. Pharmacol Ther. 101:131-181.
56. Norbury R, Mackay CE, Cowen PJ, Goodwin GM, Harmer CJ. 2007. Short-term antidepressant treatment and facial processing. Functional magnetic resonance imaging study. Br J Psychiatry. 190:531-532.
57. Nutt DJ, Forshall S, Bell C, Rich A, Sandford J, Nash J, Argyropoulos S. 1999. Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur Neuropsychopharmacol. 9(Suppl 3):S81-S86.
58. Paulus MP, Feinstein JS, Castillo G, Simmons AN, Stein MB. 2005. Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Arch Gen Psychiatry. 62:282-288.
59. Pegna AJ, Landis T, Khateb A. 2008. Electrophysiological evidence for early non-conscious processing of fearful facial expressions. Int J Psychophysiol. 70:127-136.
60. Perrin F, Pernier J, Bertrand O, Giard MH, Echallier JF. 1987. Mapping of scalp potentials by surface spline interpolation. Electroencephalogr Clin Neurophysiol. 66:75-81.
61. Pessoa L, Adolphs R. 2010. Emotion processing and the amygdala: from a low road' to 'many roads' of evaluating biological significance. Nat Rev Neurosci. 11(11):773-783.
62. Pessoa L, McKenna M, Gutierrez E, Ungerleider LG. 2002. Neural processing of emotional faces requires attention. Proc Natl Acad Sci USA. 99:11458-11463.
63. Quednow BB, Kometer M, Geyer MA, Vollenweider FX. 2012. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology. 37:630-640.
64. Savitz J, Lucki I, Drevets WC. 2009. 5-HT (1A) receptor function in major depressive disorder. Prog Neurobiol. 88:17-31.
65. Schmidt A, Kometer M, Bachmann R, Seifritz E, Vollenweider F. 2013. The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Psychopharmacology (Berl). 225(1):227-239.
66. Sharp T, Cowen PJ. 2011. 5-HT and depression: is the glass half-full? Curr Opin Pharmacol. 11:45-51.
67. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. 1998. The Mini-International Neuropsychiatric Interview (M. I. N. I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 59(Suppl 20):22-33.
68. Smith ML. 2012. Rapid processing of emotional expressions without conscious awareness. Cereb Cortex. 22:1748-1760.
69. Spinelli L, Andino SG, Lantz G, Seeck M, Michel CM. 2000. Electromagnetic inverse solutions in anatomically constrained spherical head models. Brain Topogr. 13:115-125.
70. Studerus E, Gamma A, Vollenweider FX. 2010. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One. 5:e12412.
71. Stuhrmann A, Suslow T, Dannlowski U. 2011. Facial emotion processing in major depression: a systematic review of neuroimaging findings. Biol Mood Anxiety Disord. 1:10.
72. Sugase Y, Yamane S, Ueno S, Kawano K. 1999. Global and fine information coded by single neurons in the temporal visual cortex. Nature. 400:869-873.
73. Talairach J, Tournoux P. 1988. Co-planar stereotaxic atlas of the human brain. New York: Georg Thieme Verlag, Stuttgart.
74. Tzovara A, Murray MM, Michel CM, De LM. 2012. A tutorial review of electrical neuroimaging from group-average to single-trial event-related potentials. Dev Neuropsychol. 37:518-544.
75. Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB. 2007. The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology. 32:1876-1887.
76. Vollenweider FX, Kometer M. 2010. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 11:642-651.
77. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. 1997. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology. 16:357-372.
78. Williams LM, Liddell BJ, Rathjen J, Brown KJ, Gray J, Phillips M, Young A, Gordon E. 2004. Mapping the time course of nonconscious and conscious perception of fear: an integration of central and peripheral measures. Hum Brain Mapp. 21:64-74.
79. Williams LM, Palmer D, Liddell BJ, Song L, Gordon E. 2006. The 'when' and "where' of perceiving signals of threat versus non-threat. Neuroimage. 31:458-467.
80. Wing LL, Tapson GS, Geyer MA. 1990. 5HT-2 mediation of acute behavioral effects of hallucinogens in rats. Psychopharmacology (Berl). 100:417-425.
81. Wingen M, Kuypers KP, van dV V, Formisano E, Ramaekers JG. 2008. Sustained attention and serotonin: a pharmaco-fMRI study. Hum Psychopharmacol. 23:221-230.
82. Wittchen HU, Pfister H. 1997. DIA-X-Interviews: Manual für Screening-Verfahren und Interview. Frankfurt: Swets & Zeitlinger.
83. Wronka E, Walentowska W. 2011. Attention modulates emotional expression processing. Psychophysiology. 48:1047-1056.
84. Zhen Z, Fang H, Liu J. 2013. The hierarchical brain network for face recognition. PloS one 8:e59886.